Abstract
Oral anticoagulation is the mainstay of therapy for the prevention and treatment of arterial and venous thrombosis. Landmark trials in the last decade have demonstrated the superior safety of direct acting oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation. In addition, these trials suggested superior efficacy when using apixaban or dabigatran. This led to the preferential use of DOACs as first-line therapy in nonvalvular atrial fibrillation. Similarly, superior safety observed in landmark trials of venous thromboembolism has resulted in a first-line preferential recommendation for DOACs. Recently, randomized trial data has shown that low-dose rivaroxaban decreases cardiovascular events in patients with stable coronary artery disease though this comes at a risk of increased bleeding. Such a benefit has not been clearly shown in those with acute coronary syndrome. Observational data has suggested that DOACs are noninferior to warfarin for treatment of left ventricular thrombus and stroke prevention in rheumatic mitral valve disease. Large, randomized trials are clearly needed to inform anticoagulation selection in these populations. Two areas in which data has been more definitive are heart failure with sinus rhythm and embolic stroke of unknown source. Trials in these areas have shown that the addition of DOACs does not provide any benefit but leads to increased bleeding events. Finally, in those with mechanical heart valves and left ventricular assist devices, the use of DOACs has been shown to be harmful, albeit with very limited data, and is therefore contraindicated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599–607.
Aimo A, Giugliano RP, Caterina RD. Vitamin K antagonist oral anticoagulants for mechanical heart valves. Circulation. 2018;138:1356–65.
Alcalai R, Rashad R, Butnaru A, et al. Apixaban versus warfarin in patients with left ventricular (LV) thrombus, a prospective randomized trial. Eur Heart J. 2020;41.
Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.
Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian cardiovascular society/Canadian Heart Rhythm Society Comprehensive guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36:1847–948.
Andreas M, Moayedifar R, Wieselthaler G, et al. Increased thromboembolic events with Dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial. Circ Heart Fail. 2017;10:e003709.
Barlow A, Barlow B, Reinaker T, et al. Potential role of direct oral anticoagulants in the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2019;39:837–53.
Biase LD. Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. J Am Heart Assoc. 2016;5:e002776.
Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–36.
Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2018;380:711–9.
Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–23.
Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318:1162–73.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
Cregler LL. Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J. 1992;123:1110–4.
Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2:3360–92.
Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with Dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127:634–40.
den Exter PL, Beeres SLMA, Eikenboom J, et al. Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices. Expert Rev Cardiovasc Ther. 2020;18:363–72.
Devereaux PJ, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. Eur Heart J. 2020;41:3083–91.
Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391:2325–34.
Diener H-C, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380:1906–17.
Durães AR, Bitar YSL, Lima MLG, et al. Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol. 2018;122:1047–50.
Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.
Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30.
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.
Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of Dabigatran and warfarin in patients with atrial fibrillation and Valvular heart disease. Circulation. 2016;134:589–98.
Gibson CM, Halaby R, Korjian S, et al. The safety and efficacy of full- versus reduced-dose betrixaban in the acute medically ill VTE (venous thromboembolism) prevention with extended-duration Betrixaban (APEX) trial. Am Heart J. 2017;185:93–100.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
Guimarães HP, Lopes RD, de Barros e Silva PGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383:2117–26.
Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378:2191–201.
Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with Dabigatran compared with warfarin. Circulation. 2012;126:343–8.
Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of Dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation. Circulation. 2014;129:961–70.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125–51.
Kajy M, Shokr M, Ramappa P. Use of direct Oral anticoagulants in the treatment of left ventricular Thrombus: systematic review of current literature. Am J Ther. 2020;27:e584–90.
Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s Choice—efficacy and safety of the new oral anticoagulants Dabigatran, rivaroxaban, Apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014;48:565–75.
Kim JY, Kim S-H, Myong J-P, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol. 2019;73:1123–31.
Krantz MJ, Kaul S. The ATLAS ACS 2–TIMI 51 trial and the burden of missing data: (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2–thrombolysis in myocardial infarction 51). J Am Coll Cardiol. 2013;62:777–81.
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011;366:9–19.
Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. Circulation. 2011;123:131–6.
Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–9.
Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013;34:1670–80.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2017;378:615–24.
Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020;5:685–92.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.
Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. N Engl J Med. 2020;382:1916–25.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.
The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.
The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15.
Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993;22:1004–9.
Wei A-H, Gu Z-C, Zhang C, et al. Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies. Int J Cardiol. 2018;267:1–7.
Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–22.
Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332–42.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
AlTurki, A., Proietti, R. (2021). Clinical Indications for Direct Acting Oral Anticoagulants. In: Proietti, R., AlTurki, A., Ferri, N., Russo, V., Bunch, T.J. (eds) Direct Oral Anticoagulants. Springer, Cham. https://doi.org/10.1007/978-3-030-74462-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-74462-5_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-74461-8
Online ISBN: 978-3-030-74462-5
eBook Packages: MedicineMedicine (R0)